{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:31:29Z","timestamp":1780450289423,"version":"3.54.1"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0176276","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T17:27:59Z","timestamp":1492795679000},"page":"e0176276","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study"],"prefix":"10.1371","volume":"12","author":[{"given":"Francesco","family":"Trotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Spila-Alegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Da Cas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Rajevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Venegoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Traversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"ref1","unstructured":"Global Strategy for Diagnosis, Management, and Prevention of COPD from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.goldcopd.org\/\" xlink:type=\"simple\">http:\/\/www.goldcopd.org\/<\/ext-link> (date last accessed June 1 2016)."},{"key":"ref2","unstructured":"The Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy. Year 2014. Rome: Italian Medicines Agency, 2015. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.agenziafarmaco.gov.it\/sites\/default\/files\/Rapporto_OsMed_2014_0.pdf\" xlink:type=\"simple\">http:\/\/www.agenziafarmaco.gov.it\/sites\/default\/files\/Rapporto_OsMed_2014_0.pdf<\/ext-link> (date last accessed June 1 2016)."},{"key":"ref3","unstructured":"Spiriva<sup>\u00ae<\/sup> Summary of Product Characteristics. Banca dati farmaci. Agenzia Italiana del Farmaco. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/farmaci.agenziafarmaco.gov.it\/bancadatifarmaci\/\" xlink:type=\"simple\">https:\/\/farmaci.agenziafarmaco.gov.it\/bancadatifarmaci\/<\/ext-link> (accessed 1 June 2016)."},{"key":"ref4","unstructured":"Spiriva<sup>\u00ae<\/sup> Respimat<sup>\u00ae<\/sup> Summary of Product Characteristics. Banca dati farmaci. Agenzia Italiana del Farmaco. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/farmaci.agenziafarmaco.gov.it\/bancadatifarmaci\/\" xlink:type=\"simple\">https:\/\/farmaci.agenziafarmaco.gov.it\/bancadatifarmaci\/<\/ext-link> (date last accessed June 1 2016)."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e7390","DOI":"10.1136\/bmj.e7390","article-title":"Call for worldwide withdrawal of tiotropium Respimat mist inhaler","volume":"345","author":"R Beasley","year":"2012","journal-title":"BMJ"},{"key":"ref6","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the meeting\u2013 7\u201310 January 2013. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Minutes\/2013\/02\/WC500139251.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Minutes\/2013\/02\/WC500139251.pdf<\/ext-link> (date last accessed June 1 2016)."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/thoraxjnl-2012-201926","article-title":"Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials","volume":"68","author":"YH Dong","year":"2013","journal-title":"Thorax"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1183\/09031936.00005813","article-title":"Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD","volume":"42","author":"KM Verhamme","year":"2013","journal-title":"Eur Respir J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"RA Wise","year":"2013","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1056\/NEJMe1310107","article-title":"More than just reassurance on tiotropium safety","volume":"369","author":"CR Jenkins","year":"2013","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1183\/09031936.00042213","article-title":"Tiotropium Respimat increases the risk of mortality: con","volume":"42","author":"ED Bateman","year":"2013","journal-title":"Eur Respir J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1183\/09031936.00042113","article-title":"Tiotropium Respimat increases the risk of mortality: pro","volume":"42","author":"R Beasley","year":"2013","journal-title":"Eur Respir J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/thoraxjnl-2012-202482","article-title":"Tiotropium Respimat increases the risk of mortality","volume":"68","author":"CR Jenkins","year":"2013","journal-title":"Thorax"},{"key":"ref14","unstructured":"Pulmonary-Allergy Drugs Advisory Committee. US Food and Drug Administration. Clinical briefing document, November 19 2009. Overview of the FDA background materials for an efficacy supplement for NDA# 21\u2013395, for the approved product Spiriva HandiHaler (tiotropium bromide inhalation powder), for the reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD). <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/pulmonary-allergydrugsadvisorycommittee\/ucm190463.pdf\" xlink:type=\"simple\">http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/pulmonary-allergydrugsadvisorycommittee\/ucm190463.pdf<\/ext-link> (date last accessed June 1 2016)."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/thoraxjnl-2011-201275","article-title":"Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications","volume":"68","author":"S Singh","year":"2013","journal-title":"Thorax"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-112-2-120","article-title":"Systemic effects of medications used to treat glaucoma","volume":"112","author":"DE Everitt","year":"1990","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1056\/NEJMc1314411","article-title":"Tiotropium and the risk of death in COPD","volume":"370","author":"YK Loke","year":"2014","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000355082","article-title":"What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?","volume":"87","author":"N Scichilone","year":"2014","journal-title":"Respiration"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e90145","DOI":"10.1371\/journal.pone.0090145","article-title":"Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study","volume":"9","author":"AL Kruis","year":"2014","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e006619","DOI":"10.1136\/bmjopen-2014-006619","article-title":"Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study","volume":"5","author":"F Trotta","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"ref21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/bcp.12808","article-title":"Tiotropium Respimat(<sup>\u00ae<\/sup>) vs. HandiHaler(<sup>\u00ae<\/sup>): real-life usage and TIOSPIR trial generalizability","volume":"81","author":"S Schmiedl","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"15067","DOI":"10.1038\/npjpcrm.2015.67","article-title":"Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial","volume":"25","author":"R Wise","year":"2015","journal-title":"NPJ Prim Care Respir Med"},{"key":"ref23","first-page":"239","article-title":"Tiotropium HandiHaler(<sup>\u00ae<\/sup>) and Respimat(<sup>\u00ae<\/sup>) in COPD: a pooled safety analysis","volume":"10","author":"DM Halpin","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0176276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T20:21:39Z","timestamp":1540326099000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0176276"}},"subtitle":[],"editor":[{"given":"Ping-Hsun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0176276","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]}}}